EP3142791A1 - Verfahren zum testen von verbindungen auf lebenden zellen - Google Patents
Verfahren zum testen von verbindungen auf lebenden zellenInfo
- Publication number
- EP3142791A1 EP3142791A1 EP15771240.7A EP15771240A EP3142791A1 EP 3142791 A1 EP3142791 A1 EP 3142791A1 EP 15771240 A EP15771240 A EP 15771240A EP 3142791 A1 EP3142791 A1 EP 3142791A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fluid
- cell
- channel
- cells
- partitions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims description 98
- 150000001875 compounds Chemical class 0.000 title description 21
- 238000012360 testing method Methods 0.000 title description 4
- 238000005192 partition Methods 0.000 claims abstract description 236
- 239000012530 fluid Substances 0.000 claims abstract description 206
- 239000007788 liquid Substances 0.000 claims abstract description 62
- 210000004027 cell Anatomy 0.000 claims description 281
- 239000003814 drug Substances 0.000 claims description 63
- 229940079593 drug Drugs 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 19
- 210000000130 stem cell Anatomy 0.000 claims description 18
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 238000011534 incubation Methods 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 239000002699 waste material Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 abstract description 20
- 239000000126 substance Substances 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 238000012546 transfer Methods 0.000 abstract description 4
- 239000003921 oil Substances 0.000 description 38
- 235000019198 oils Nutrition 0.000 description 37
- 239000002502 liposome Substances 0.000 description 28
- 239000002609 medium Substances 0.000 description 28
- 150000002632 lipids Chemical group 0.000 description 26
- 239000000758 substrate Substances 0.000 description 25
- 241000894007 species Species 0.000 description 22
- 239000012071 phase Substances 0.000 description 21
- 206010006187 Breast cancer Diseases 0.000 description 20
- 208000026310 Breast neoplasm Diseases 0.000 description 20
- 239000002245 particle Substances 0.000 description 19
- 230000003833 cell viability Effects 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 239000004094 surface-active agent Substances 0.000 description 16
- 239000000693 micelle Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 14
- 229910002092 carbon dioxide Inorganic materials 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000007789 gas Substances 0.000 description 9
- 230000036571 hydration Effects 0.000 description 9
- 238000006703 hydration reaction Methods 0.000 description 9
- -1 molecules Substances 0.000 description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 8
- 229960004316 cisplatin Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 7
- 238000004581 coalescence Methods 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000005684 electric field Effects 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000000717 retained effect Effects 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000000890 drug combination Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 4
- 229960002411 imatinib Drugs 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000005499 meniscus Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012062 aqueous buffer Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- 238000010459 TALEN Methods 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 230000008568 cell cell communication Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- XPBBUZJBQWWFFJ-UHFFFAOYSA-N fluorosilane Chemical compound [SiH3]F XPBBUZJBQWWFFJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NGDLSKPZMOTRTR-OAPYJULQSA-N (4z)-4-heptadecylidene-3-hexadecyloxetan-2-one Chemical compound CCCCCCCCCCCCCCCC\C=C1/OC(=O)C1CCCCCCCCCCCCCCCC NGDLSKPZMOTRTR-OAPYJULQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- JKTAIYGNOFSMCE-UHFFFAOYSA-N 2,3-di(nonyl)phenol Chemical class CCCCCCCCCC1=CC=CC(O)=C1CCCCCCCCC JKTAIYGNOFSMCE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000005447 environmental material Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- PISDRBMXQBSCIP-UHFFFAOYSA-N trichloro(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)CC[Si](Cl)(Cl)Cl PISDRBMXQBSCIP-UHFFFAOYSA-N 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000003631 wet chemical etching Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
- B01L3/50857—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates using arrays or bundles of open capillaries for holding samples
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/40—Mixing liquids with liquids; Emulsifying
- B01F23/41—Emulsifying
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/30—Micromixers
- B01F33/302—Micromixers the materials to be mixed flowing in the form of droplets
- B01F33/3021—Micromixers the materials to be mixed flowing in the form of droplets the components to be mixed being combined in a single independent droplet, e.g. these droplets being divided by a non-miscible fluid or consisting of independent droplets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/30—Micromixers
- B01F33/3031—Micromixers using electro-hydrodynamic [EHD] or electro-kinetic [EKI] phenomena to mix or move the fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F33/00—Other mixers; Mixing plants; Combinations of mixers
- B01F33/30—Micromixers
- B01F33/3035—Micromixers using surface tension to mix, move or hold the fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5025—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures for parallel transport of multiple samples
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502738—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by integrated valves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502769—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements
- B01L3/502784—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements specially adapted for droplet or plug flow, e.g. digital microfluidics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L7/00—Heating or cooling apparatus; Heat insulating devices
- B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
- B01L7/525—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples with physical movement of samples between temperature zones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/12—Well or multiwell plates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
- B01F2101/23—Mixing of laboratory samples e.g. in preparation of analysing or testing properties of materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/40—Mixing liquids with liquids; Emulsifying
- B01F23/41—Emulsifying
- B01F23/414—Emulsifying characterised by the internal structure of the emulsion
- B01F23/4143—Microemulsions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
- B01F23/40—Mixing liquids with liquids; Emulsifying
- B01F23/41—Emulsifying
- B01F23/414—Emulsifying characterised by the internal structure of the emulsion
- B01F23/4145—Emulsions of oils, e.g. fuel, and water
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/026—Fluid interfacing between devices or objects, e.g. connectors, inlet details
- B01L2200/027—Fluid interfacing between devices or objects, e.g. connectors, inlet details for microfluidic devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0668—Trapping microscopic beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0673—Handling of plugs of fluid surrounded by immiscible fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/12—Specific details about manufacturing devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/02—Identification, exchange or storage of information
- B01L2300/021—Identification, e.g. bar codes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0654—Lenses; Optical fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0663—Whole sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0874—Three dimensional network
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/088—Channel loops
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
- B01L2300/161—Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
- B01L2300/165—Specific details about hydrophobic, oleophobic surfaces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
- B01L2300/1822—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using Peltier elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1805—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks
- B01L2300/1827—Conductive heating, heat from thermostatted solids is conducted to receptacles, e.g. heating plates, blocks using resistive heater
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/18—Means for temperature control
- B01L2300/1861—Means for temperature control using radiation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/02—Drop detachment mechanisms of single droplets from nozzles or pins
- B01L2400/022—Drop detachment mechanisms of single droplets from nozzles or pins droplet contacts the surface of the receptacle
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0415—Moving fluids with specific forces or mechanical means specific forces electrical forces, e.g. electrokinetic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0457—Moving fluids with specific forces or mechanical means specific forces passive flow or gravitation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0633—Valves, specific forms thereof with moving parts
- B01L2400/065—Valves, specific forms thereof with moving parts sliding valves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0688—Valves, specific forms thereof surface tension valves, capillary stop, capillary break
Definitions
- the invention generally relates to methods of disease modeling in living cells in a microfluidic device.
- Type 2 Diabetes a chronic disease afflicting millions of Americans.
- an afflicted person must submit to insulin therapy which requires daily monitoring of blood sugar levels and daily insulin injections.
- insulin therapy a person with Type 2 Diabetes faces the potential damage to nerves and small blood vessels of the eyes, kidneys, and heart. Damage to these tissues ultimately results in heart attack or stroke.
- hospital-acquired staph infections are particularly troublesome. Many strains of staphylococcus encountered in hospitals are resistant to known antibiotics. Patient care would be greatly improved if researchers were to discover a drug that could knock out antibiotic resistant bacteria.
- the invention provides mechanical devices that can be used to combine reagents and discover their effects on living cells in high-throughput screenings, thus allowing tens of millions of novel compounds to be rapidly screened to discover a compound with lifesaving potential.
- Devices of the invention use gravity and surface tension to combine liquids and control flow, thus avoiding pumps and electrodes and providing an environment suitable to living cells.
- Open- ended channels retain liquid by surface tension and liquids flows from one channel to another only when those channels are aligned and in proximity.
- Liquids containing agents, such as drugs or chemicals are held in one or more individual source channels.
- the device includes a mechanical system that controls the operation of channels relative to one another. A receiving channel passes among the source channels, aligning with each in turn, to pick up liquids from those channels.
- the receiving channel can combine one, two, three, four, or any number of drugs in a fluid partition.
- Living cells can be introduced into the fluid partitions by operation of the device.
- the partitions can be, for example, water-in-oil-in-water emulsions, allowing the cells to be isolated within the partitions but also allowing nutrients and waste to diffuse into and out of the partitions.
- devices of the invention can be used to assay for the effects of those compounds on the cells. Since the invention provides devices for creating and analyzing millions of combinations of drugs, devices of the invention may thus be used to discover unexpected or synergistic effects for new combinations of known drugs and to possibly discover a valuable antibiotic or a treatment for a disease.
- the invention provides a method for analyzing cells in partitions.
- the method includes holding a living cell in a fluid partition in a first open-ended channel and introducing a liquid that includes an agent into the partition by aligning at least a portion of the first open ended channel with a second open ended channel from which the fluid is provided.
- the contents of the fluid partition are analyzed, e.g., to determine an effect of the agent on the living cell.
- aligning comprises contacting a liquid in the first channel with a liquid in the second channel.
- Any suitable cell can be held in the fluid partition such as a stem cell (e.g., a pluripotent stem cell modelling a disease state).
- the cell may be infected with a contagious disease or it may be exposed to a virus, pathogen, or bacteria.
- a concentration gradient may be created to remove waste from the fluid partition.
- the agent in the liquid includes at least one drug molecule.
- aspects of the invention provide a method for analyzing cells in partitions.
- the method includes containing at least one cell in a first fluid compartment of a fluid partition in a first open ended channel— wherein the fluid partition comprises at least two fluid compartments— and introducing a fluid into the partition by aligning the first open ended channel with a second open ended channel from which the fluid is provided.
- the contents of the partition are analyzed.
- the first fluid compartment may contain a first cell type and a second fluid compartment may contain a second cell type.
- the first fluid compartment contains a stem cell and a second fluid compartment contains an agent (e.g., a virus, a drug molecule, a bacterium, or a protein).
- the stem cell may be analyzed after incubation with the agent.
- the invention provides a device for analyzing cells in partitions.
- the device includes a first open-ended channel configured to hold a living cell in a fluid partition and a second open-ended channel operably coupled to a control mechanism. Operation of the control mechanism aligns at least a portion of the first open-ended channel with the second channel, thereby introducing a liquid comprising an agent into the fluid partition.
- the device can be used to analyze the effects of the agent on the living cell.
- aligning comprises contacting a liquid in the first channel with a liquid in the second channel.
- Any suitable cell can be held in the fluid partition such as a stem cell (e.g., a pluripotent stem cell (PSC) modelling a disease state).
- PSC pluripotent stem cell
- a concentration gradient may be created to remove waste from the fluid partition.
- the agent in the liquid includes at least one drug molecule.
- cells are isolated in fluid partitions, such as liposomes, micelles, emulsions, or droplets.
- An agent such as a small molecule, a drug compound, a protein, etc.
- the cell, or the fluid within the partition is analyzed for changes in cellular functions.
- cellular based assays are accomplished at a high-throughput level.
- Methods and devices of the invention use open-ended channels.
- the open-ended channels are oriented and configured so that fluid only flows between two open-ended channels when they are aligned. When the open-ended channels are not aligned, flow does not occur.
- fluids containing cells are manipulated and controlled in a gravity-based system that preserves cell integrity.
- the cells are stem cells.
- the stem cells or pluripotent stem cells can be induced to model a disease state, such as cancer, diabetes, Huntington's disease, rheumatoid arthritis, etc.
- a disease-state cell is used.
- beta-cells from a Type 2 Diabetes patient may be investigated or analyzed.
- the stem cells may be infected with a contagious disease, such as a virus or a pathogen.
- the methods of the invention may use a wide variety of cells, whether native cells, or induced disease state cells.
- the cells are exposed to an agent.
- the agent may be a drug compound, a combination of drug compounds, a protein, etc.
- the agent may be introduced into the partition containing the cell. After incubation for a period of time, the cell or the fluid around the cell may be analyzed to discern alterations in cellular function.
- a cell is contained within a fluid partition and the fluid partition contains multiple compartments.
- the fluid partition may contain two aqueous compartments, wherein at least one compartment contains a cell.
- An agent, virus, or pathogen may be found in the other compartment.
- a cell may be contained in each aqueous fluid compartment with an agent introduced into each compartment. After a period of incubation, alterations in cellular function or cellular products are investigated and analyzed.
- Genetically modified cells may be used to model a disease.
- Various cell types e.g. heart, lung, kidney, brain, etc., may be genetically modified or infected to model a disease.
- the modified or infected cells may be screened against a multitude of compounds, molecules, or agents to comprehensively investigate toxicity and efficacy.
- a wide variety of cell types, or cell models can be combined with various combinations of drugs.
- FIGS. 1A-1B show an embodiment of a system of the invention.
- FIGS. 2A-2C depict alternate configurations of the channels.
- FIGS. 3A-3C depict a multi-channel system.
- FIGS. 5A-5B depict a multi-compartment emulsion of the invention.
- FIG. 6 depicts a microfluidic channel.
- FIG. 7 depicts the results of off-patent drugs and drug combinations of MCF-7 cells.
- FIG. 8 depicts a dose response curve of the effect of antibiotics on E. coli cells.
- FIG. 9 depicts a dose response curve of the effects of antibiotics on E. coli cells.
- FIG. 10 depicts a dose response curve for the effect of drugs on MCF-7 cells.
- FIG. 11 depicts PSC drug treatments in droplets.
- FIG. 12 depicts PSC in droplets.
- FIG. 13 depicts cell growth and viability in droplets.
- FIG. 14 depicts a schematic of the channels and fluid flow.
- FIG. 15 is a graph of dispensing time versus droplet volume.
- FIGS. 16A and 16B depict substrates on a mechanical subsystem.
- Methods of the invention relate to forming multi-liquid partitions within a partition, where the liquid partitions contain at least one cell.
- the liquid partitions may contain the same type of cell, or differing cell types.
- Cells may be altered to express a disease, or may be transfected with a virus, bacteria, element, molecule, etc. Once infected, the cells may be exposed to a molecule, compound, or other agent.
- Multiple partitions may be processed and manipulated in sliding microfluidic channels. In some embodiments, the contents of the partitions or the cells are analyzed.
- FIGS. 1A-1B show an exemplary embodiment of a microfluidic system 200 in which the methods of the invention are performed.
- FIGS. 1 A-1B are described in the context of two channels for the sake of simplicity. However, the skilled artisan will recognize that the invention is not limited to two channels, and the invention encompasses systems designed with any number of channels, as will be described in additional embodiments below.
- Microfluidic system 200 includes a first channel 201 having an open end 202, and a second channel 203 having an open end 204.
- the first and second channels are slidable relative to each other such that when the open end 202 of the first channel 201 and the open end 204 of the second channel 203 are aligned with each other, fluid 205 flows from the first channel 201 into the second channel 203 (in FIG. IB, flow is shown by a large downward pointing arrow within channel 203).
- FIG. IB flow is shown by a large downward pointing arrow within channel 203.
- fluid 205 does not flow within the first channel 201 and the second channel 203 (FIG. 2A).
- Alignment of channels can include complete or partial alignment.
- complete alignment the center axes of two microfluidic channels are aligned.
- partial alignment the center axes are not aligned, however, there is partial overlap of the first and second channels such that the distance between the center axes is sufficiently small so that flow between the two microfluidic channels occurs.
- complete misalignment there is no overlap between the channels and the distance between the center axes is sufficiently great so that flow between the two microfluidic channels does not occur.
- alignment is meant to encompass both complete and partial alignment.
- the device of the invention flows fluid between two
- microfluidic channels even in the cases of partial alignment.
- the channels may slide in any direction relative to each other, e.g., horizontally, vertically, diagonally, etc.
- the first channel 201 and the second channel 203 are horizontally slideable relative to each other as shown in FIGS. 1A-1B (horizontal arrows).
- FIGS. 1A-1B show second channel 203 being slideable relative to first channel 201, which remains stationary.
- it may be first channel 201 that is slidable relative to second channel 203, which remains stationary.
- both the first channel 201 and the second channel 203 are slidable, that is, neither channel remains stationary and both channels are movable.
- the open end 202 of the first channel 201 and the open end 204 of the second channel 203 are exposed to atmospheric pressure.
- the first channel 201 and second channel 203 may be arranged in relation to each other such that an air gap 206 exists between the channels. As shown in FIGS. 1A-1B, when the open end 202 of the first channel 201 and the open end 204 of the second channel 203 are aligned with each other, fluid 205 from the first channel 201 bridges the air gap 206 and enters the second channel 203.
- the air gap may comprise any known gas, at any suitable temperature and pressure.
- the air gap may be at atmospheric pressure and comprise of air.
- the air gap is not limited to atmospheric pressure or air.
- the devices of the present invention may be completely or partially enclosed within a chamber and the chamber may be filled with a gas other than air.
- the pressure can be above or below atmospheric pressure and the temperature can be at, above, or below room temperature, which is about 37 degrees Celsius.
- gravitational force is used to produce and control flow within the system.
- the first channel 201 and the second channel 203 are arranged (e.g., arranged vertically) such that gravity causes flow of fluid 205 within the first channel 201 and second channel 203 when the open end 202 of the first channel 201 and the open end 204 of the second channel 203 are aligned with each other.
- the first channel 201 and second channel 203 may be configured such that when they are not aligned, fluid 205 does not flow within the first channel 201 and/or second channel 203. That can be achieved in numerous different ways, such as by adjusting length of the channels, internal diameter of the channels, viscosity of the fluid(s) within the channels, surface tension of the fluid(s) within the channels, and/or density of the fluid(s) within the channels.
- FIGS. 2A-2C depict a multi-channel system configured to allow microfluidic channels to slide or move relative to each other to alter alignment of the channels.
- FIG. 2A shows multiple microfluidic channels 501, 503, and 505 which are open at ends 530, 532, and 534.
- Microfluidic channels 501, 503, and 3505 each may contain a fluid, for example microfluidic channel 501 contains fluid 502. Fluids 502, 503, and 506 may be the same or different.
- microfluidic channels 501, 503, and 505 may be slidable or moveable together or independent of one another.
- FIG. 2A also depicts microfluidic channels 509 and 511 which are open ended at 540 and 541.
- Microfluidic channels 509 and 511 are shown in FIG. 2A to contain fluids 550 and 551.
- microfluidic channels 509 and 511 are not required to contain fluids and may not contain fluids.
- Microfluidic channels 509 and 511 may be moved independent of one another or may be moved together. As shown in FIG. 2A, microfluidic channels 509 and 511 are positioned to be disengaged from microfluidic channels 501, 503, and 505. In this positioning of the microfluidic channels, microfluidic channels 501, 503, and 505 are prevented from flowing fluid due to the physical properties of the microfluidic channel and the fluid, e.g. surface tension.
- Microfluidic channels 509 and 511 may be slid or moved to align with any of the microfluidic channels 501, 503, or 505.
- FIG. 2B depicts microfluidic channels 509 and 511 having been moved or slid relative to microfluidic channels 501, 503, or 505.
- microfluidic channel 509 has been slid to engage at least one of microfluidic channels 501, 503, and 505. Moving or sliding of microfluidic channel 509 or 511 may involve movement in any plane or direction.
- microfluidic channel 503 is aligned with microfluidic channel 509. The alignment may cause an air gap 513.
- microfluidic channels 503 and 509 are aligned so that the microfluidic channels are flush. Rather, an air gap 513 may be present between the two microfluidic channels.
- the arrangement of microfluidic channels 503 and 509 is such when the channels are aligned, fluid bridges the air gap 513 and flows from microfluidic channel 503 into microfluidic channel 509. In this positioning, microfluidic channel 509 receives fluid 503 from microfluidic channel 503.
- microfluidic channels of the invention may be slid or moved in several iterations.
- microfluidic channel 509 has been slid to align with microfluidic channel 501.
- microfluidic channel 509 was aligned with microfluidic channel 503 and received fluid 503.
- Microfluidic channel 509 now contains fluid 503 and fluid 502. In this embodiment, fluids are mixed from two different microfluidic channels.
- microfluidic channel 511 is aligned with microfluidic channel 505. It should be appreciated that microfluidic channels 509 and 511 could be slid or moved at the same time, or independently of each other, depending on the configuration of microfluidic channels 509 and 511 and their respective substrates.
- FIGS. 2A-2C serve to illustrate how two levels of microfluidic channels can align to direct the flow of partitions within a microfluidic system. It should be appreciated that numerous levels of microfluidic channels may include a multichannel system, as discussed below.
- the microfluidic device of the invention may be utilized to flow partitions within microfluidic channels.
- the microfluidic channels of the present invention can be aligned to transfer liquids from one to another.
- the microfluidic system may be used to flow partitions within and between microfluidic channels.
- the partitions may be provided within a carrier fluid, such as an oil.
- a fluid (fluid 502, see FIGS. 2A-2C) within a channel (channel 501) contains at least one partition. Aligning channel 509 with channel 502 allows for at least one partition to flow into channel 509.
- the partition can be a liposome, a droplet, etc.
- the partition can contain a cell, such as a stem cell or a pluripotent stem cell.
- Channel 509 can then align with channel 503 so that liquid within channel 503 flows into channel 509.
- the liquid in channel 509 merges or coalescences with the partition (discussed below).
- the liquid can contain any suitable agent such as a virus, pathogen, bacteria, drug, therapeutic agent, etc.
- the partition may be flowed into a container (see container 550 in FIG. 2C) and detected or analyzed using a detector 551.
- a detector may be included with or within devices of the invention.
- the detector can be optical or electrical detectors or combinations thereof.
- suitable detection apparatuses include optical waveguides, microscopes, diodes, light stimulating devices, (e.g., lasers), photo multiplier tubes, and processors (e.g., computers and software), and combinations thereof, which cooperate to detect a signal representative of a characteristic, marker, or reporter, and to determine and direct the measurement or the sorting action at a sorting module.
- light stimulating devices e.g., lasers
- photo multiplier tubes e.g., computers and software
- a portion of the multichannel system comprising one or more microfluidic channels is in thermal contact with a thermal regulator.
- the thermal regulator can be any device that regulates temperature. This includes, for example, resistive wires that heat up when a voltage is applied , resistive heaters, fans for sending hot or cold air toward the isolated portion, Peltier devices, infrared (IR) heat sources such as projection bulbs, circulating liquids or gases in a contained device, and microwave heating.
- IR infrared
- a thermal regulator controls the temperature of liquids or partitions within a device of the invention, e.g., for incubation or control of chemical reactions.
- the ability of the thermal regulator to be programmed for different temperatures and incubation times, together with other aspects of the invention to control the introduction of samples, reactants and other reagents into the microfluidic channels provides the ability to control reaction times, temperatures, and reaction conditions within the microfluidic channels.
- a portion of the multichannel system is in contact with a heat spreader of the thermal regulator. There may be an air gap between the portion of the microfluidic device and the heating element of the thermal regulator.
- the microfluidic device can be secured to the thermal regulator by one or more bolts, screws, pins, clips, brackets, or other such securing devices.
- the fluid within the microfluidic channel contains partitions.
- partitions may be composed or various fluids and various components.
- the microfluidic channels of the invention can be slid to align in order to select the path of the partitions within the microfluidic system. As the partitions flow through the channels, flow can be stopped within a microfluidic channel by misalignment with another microfluidic channel. Flow may resume once the microfluidic channel is aligned with another microfluidic channel such that flow occurs therebetween.
- Devices and methods of the invention may use a multiple channel system.
- FIGS. 3A-3C depict a multi-channel system configured to allow microfluidic channels to slide or move relative to one another to alter alignment of the channels.
- FIG. 3A shows multiple microfluidic channels 701, 703, and 705 which are open at ends 730, 732, and 734.
- Microfluidic channels 701, 703, and 705 each may contain a liquid.
- microfluidic channel 701 contains liquid 702.
- Liquids 702, 703, and 706 may be composed of the same components or may be composed of differing components.
- Each liquid 702, 703, and 706 is retained in the microfluidic channel by forces such as surface tension (without being bound by an mechanism, the force holding a liquid in an open-ended channel regardless of the presence of gravity may include contributions from surface tension, "wicking" or capillary forces, electrostatic forces, others, or combinations thereof).
- Each microfluidic channel 701, 703, and 705 may contain one or any number of partitions 760, 761, and 762.
- the partitions may be composed of various fluids and components. Additionally, the partitions 701, 703, and 705 may each include the same or different materials and components. Additionally, microfluidic channels 701, 703, and 705 may be slidable or moveable together or independent of one another.
- FIG. 3A also depicts
- microfluidic channels 709 and 711 which are open ended at 740 and 741. It should be appreciated that microfluidic channels 709 and 711 are shown in FIG. 3 A to contain fluids 750 and 751. However, it should also be appreciated that microfluidic channels 709 and 711 may not contain liquids. Microfluidic channels 709 and 711 may be moved independent of one another or may be moved together. It is an aspect of the invention that microfluidic channels may be arranged in any configuration and manner. As shown in FIG. 3 A, microfluidic channels 709 and 711 are positioned to be disengaged from microfluidic channels 701, 703, and 705. In this positioning of the microfluidic channels, microfluidic channels 701, 703, and 705 are prevented from flowing liquid due to the physical properties of the microfluidic channel and the immiscible fluid, e.g. surface tension, as discussed above.
- the immiscible fluid e.g. surface tension
- Microfluidic channels 709 and 711 may be slid or moved to align with any of the microfluidic channels 701, 703, or 705.
- FIG. 3B depicts microfluidic channels 709 and 711 that has been moved or slid relative to microfluidic channels 701, 703, or 705.
- microfluidic channel 709 has been slid to engage at least one of microfluidic channels 701, 703, and 705. It should be appreciated that the moving or sliding of microfluidic channel 709 or 711 may involve movement in any plane or direction.
- microfluidic channel 703 is aligned with microfluidic channel 709. The alignment may cause an air gap 713.
- microfluidic channels 703 and 709 may be aligned so that the microfluidic channels are flush. Rather, an air gap 713 may be present between the two microfluidic channels.
- the alignment of microfluidic channels 703 and 709 forms an air gap at 713.
- the formation of the air gap 713 results in a portion of fluid spanning air gap 713 and allows for fluid 703 and partitions 761 to flow from microfluidic channel 703 into microfluidic channel 709. In this positioning, microfluidic channel 709 receives fluid 703 and partitions 761 from microfluidic channel 703.
- microfluidic channels of the invention may be slid or move in several iterations.
- microfluidic channel 709 has been slid to align with microfluidic channel 701.
- microfluidic channel 709 was aligned with microfluidic channel 703 and received fluid 703 and partitions 761.
- Microfluidic channel 709 now contains liquid 703 and liquid 702 and partitions 761 and 760.
- the components of the two different microfluidic channels are mixed.
- microfluidic channel 711 is aligned with microfluidic channel 305.
- Microfluidic channels 709 and 711 can be slid or moved at the same time, or independently of each other, depending on the configuration of microfluidic channels 709 and 711 and their respective substrates.
- Multichannel systems of the invention may include numerous channels aligned in various planes of space.
- FIGS. 3A - 3C serve to illustrate how two levels of microfluidic channels can align to direct the flow of partitions within a microfluidic system.
- the channels may be slid manually, by a gear, by a robotic stage, by a motor, etc.
- Systems of the invention can also be used for partition merging or coalescing.
- the fluidic partitions may be of unequal size in certain cases.
- one or more series of partitions may each consist essentially of a substantially uniform number of entities of a species therein (i.e., molecules, cells, particles, etc.).
- the fluidic partitions may be coalesced to start a reaction, and/or to stop a reaction, in some cases. For instance, a reaction may be initiated when a species in a first partition contacts a species in a second partition after the partitions coalesce, or a first partition may contain an ongoing reaction and a second partition may contain a species that inhibits the reaction.
- Embodiments of the invention are directed to alignment of microfluidic channels to promote the coalescence of fluidic partitions.
- Partitions may coalesce upon application of an electric field.
- the applied electric field may induce a charge, or at least a partial charge, on a fluidic partition surrounded by an immiscible fluid.
- partitions are induced to assume opposite charges or electric dipoles on the surfaces closest to each other, causing the partitions to coalesce.
- two partitions may fuse by creating a liquid bridge between them, which may occur due to the charge-charge interactions or to reduce surface tensions.
- the creation of the liquid bridge between the two partitions allows the two partitions to exchange material or coalesce into one partition.
- the invention provides for the coalescence of two separate partitions into one coalesced partition in systems where such coalescence ordinarily is unable to occur, e.g., due to size or surface tension.
- Devices of the invention can also be used for partition merging or coalescing.
- the fluidic partitions may be of unequal size in certain cases.
- one or more series of partitions may each consist essentially of a substantially uniform number of entities of a species therein (i.e., molecules, cells, particles, etc.).
- the fluidic partitions may be coalesced to start a reaction, and/or to stop a reaction, in some cases. For instance, a reaction may be initiated when a species in a first partition contacts a species in a second partition after the partitions coalesce, or a first partition may contain an ongoing reaction and a second partition may contain a species that inhibits the reaction.
- Embodiments of the invention are directed to alignment of microfluidic channels to promote the coalescence of fluidic partitions.
- partitions are merged without the use of electrodes or electric fields. Coalescing of partitions without the application of an electric field is described by Xu et al, "Droplet Coalescence in Microfluidic Systems," Micro and Nanosystems, 2011, 3, 131-136, which is incorporated by reference.
- the method described by Xu et al. merges droplets by allowing two droplets to have close contact with each other, causing the liquids of the two droplets to form a thin bridge between the two partitions.
- the methods described by Xu et al. are passive, where an external energy source is not needed. Passive merging can also be
- partition merging may be accomplished using a widening channel follow by a narrower channel. In this geometry the partition velocity decreases in the widening channel, after which it increases again upon entry in the narrow channel.
- microfluidic channels 801 and 803 contain carrier fluid and at least one partition.
- Microfluidic channel 805 is not aligned with either microfluidic channel 801 or 803.
- the carrier fluid and the partitions are not able to flow out of the open end of microfluidic channels 801 or 803.
- FIG. 4B shows microfluidic channel 803 aligned with microfluidic channel 805, thereby allowing flow of carrier fluid and partitions between microfluidic channel 803 and microfluidic channel 805.
- FIG. 4C shows an embodiment in which microfluidic channel 805 received a partition when aligned to microfluidic channel 803, and the alignment is then disengaged.
- FIG. 4D shows microfluidic channel 805 aligned with microfluidic channel 801 to receive carrier fluid and a partition from microfluidic channel 801. The partitions within microfluidic channel 805 can placed close together, causing passive merging.
- microfluidic channel 805 the partitions are coalesced 807.
- coalesces may be accomplished by the application of an electric field.
- electrodes may be located proximate to microfluidic channels to create an electric field to cause partitions to coalesce.
- passive merging can be accomplish by positioning partitions next to one another. In some embodiments in which partitions are present, aligning microfluidic channels to position partitions close together causes passive merging, as described above.
- an open channel generally will include characteristics that facilitate control over fluid transport, e.g., structural characteristics (an elongated indentation) and/or physical or chemical characteristics (hydrophobicity vs. hydrophilicity) and/or other characteristics that can exert a force (e.g., a containing force) on a fluid.
- the fluid within the channel may partially or completely fill the channel.
- the fluid may be held or confined within the channel or a portion of the channel in some fashion, for example, using surface tension (e.g., such that the fluid is held within the channel within a meniscus, such as a concave or convex meniscus).
- some (or all) of the channels may be of a particular size.
- channels may have a largest dimension perpendicular to fluid flow ranging from 5 mm to about 10 nm.
- larger channels, tubes, etc. can be used to store fluids in bulk or deliver a fluid to the channel.
- the channel is a capillary.
- microfluidic channels of the invention are configured such that liquid is retained within the microfluidic channel when it is completely out of alignment with another microfluidic channel (e.g., no overlap between open ends of channels). Liquid may be retained within the microfluidic channel due to forces such as surface tension.
- the flow in a microfluidic channel system, as shown in FIG. 6, with a height of h, an internal diameter of d, a length of L, a fluid velocity of u, a fluid density of p, gravitation force of g, fluid viscosity of ⁇ , and surface tension of y, can be represented by the equation:
- the volume of fluid that flows from one channel to another channel depends on the amount of time that the channels are aligned. As shown in FIG. 14, two channels 2800 and 2801 are aligned. Q is the flow rate in each channel, v is the velocity of the sliding channel, and r is the radius of the channel. Time when flowing is equal to nr/v, where n is the fraction of the lateral distance. As channel 2801 moves at a velocity relative to channel 2800, a volume of fluid flows from channel 2800 into channel 2801. G is the gap between the channels, and g is the force of gravity.
- the following equations denote the time required to dispense a volume, V from one channel to another channel. R is the resistance, P is the pressure, and u is the velocity.
- FIG. 15 is a graph showing dispensing time (t) versus droplet volumes produced (nL) for varying vena contracta.
- the vena contracta means that average r is constantly changing, and can be averaged to r/2.
- the dimensions of the channel may be chosen such that fluid is able to freely flow through the channel when channels are aligned and will not flow when channels are out of alignment with each other.
- the dimensions of the channel may also be chosen, for example, to allow a certain volumetric or linear flow rate of fluid in the channel.
- the number of channels and the shape of the channels can be varied by any method known to those of ordinary skill in the art.
- the channels of the device of the present invention can be of any geometry as described.
- the channels of the device can comprise a specific geometry such that the contents of the channel are manipulated, e.g., sorted, mixed, prevent clogging, etc.
- the channels of the device may preferably be square, with a diameter between about 2 microns and 1 mm. This geometry facilitates an orderly flow of partitions in the channels.
- the channels may have a coating which minimizes adhesion.
- a coating may be intrinsic to the material from which the device is manufactured, or it may be applied after the structural aspects of the channels have been microfabricated. Any suitable material may be used for coating a surface of a channel.
- One such material is
- the surface of the channels of the microfluidic system can be coated with any anti-wetting or blocking agent for the dispersed phase.
- the channel can be coated with any protein to prevent adhesion of the biological/chemical sample.
- the channels are coated with BSA, PEG-silane and/or fluorosilane.
- BSA polytetrafluoroethylene
- PEG-silane polytetrafluoroethylene
- fluorosilane 5 mg/ml BSA is sufficient to prevent attachment and prevent clogging.
- the channels can be coated with a cyclized transparent optical polymer obtained by copolymerization of perfluoro (alkenyl vinyl ethers), such as the type sold by Asahi Glass Co. under the trademark Cytop.
- the coating is applied from a 0.1-0.5 wt % solution of Cytop CTL-809M in CT-Solv 180. This solution can be injected into the channels of a microfluidic device via a plastic syringe. The device can then be heated to about 90°C. for 2 hours, followed by heating at 200°C for an additional 2 hours.
- the channels can be coated with a hydrophobic coating of the type sold by PPG Industries, Inc.
- Aquapel e.g., perfluoroalkylalkylsilane surface treatment of plastic and coated plastic substrate surfaces in conjunction with the use of a silica primer layer
- Aquapel e.g., perfluoroalkylalkylsilane surface treatment of plastic and coated plastic substrate surfaces in conjunction with the use of a silica primer layer
- U.S. Pat. No. 5,523,162 which patent is hereby incorporated by reference.
- the surface of the channels in the microfluidic device can be also fluorinated to prevent undesired wetting behaviors.
- a microfluidic device can be placed in a
- polycarbonate dessicator with an open bottle of (tridecafluoro-1,1,2,2- tetrahydrooctyl)trichlorosilane.
- the dessicator is evacuated for 5 minutes, and then sealed for 20- 40 minutes.
- the dessicator is then backfilled with air and removed.
- This approach uses a simple diffusion mechanism to enable facile infiltration of channels of the microfluidic device with the fluorosilane and can be readily scaled up for simultaneous device fluorination.
- microfluidic substrates are well known in the art.
- the substrates may be formed by several different types of materials, such as silicon, plastic, quartz, glass, plastic, or other suitable materials.
- the size, shape and complexity of the microfluidic channels and structures that can be used in the microfluidic device depends on the materials used and the fabrication processes available for those materials.
- Typical system fabrication includes making trenches in a conducting material (silicon) or in a non-conducting substrate (e.g., glass or plastic) and converting them to channels by bonding a cover plate to the substrate. See for example, U.S. Patent 6,210,986. In addition, for example, U.S. Patent No.
- 5,885,470 teaches a microfluidic device having application in chemistry, biotechnology, and molecular biology that provides precise control of fluids by forming various grooves or channels and chambers in a polymeric substrate.
- the process of forming microfluidic channels in a substrate can include wet chemical etching, photolithographic techniques, controlled vapor deposition, and laser drilling into a substrate.
- Alternative techniques for constructing microfluidic channels may be employed in the fabrication of the device of the invention. For example, in Stjernstrom and Roeraade, Method for Fabrication of Microfluidic Systems in Glass, J. Micromechanics and Microenginneering, 8:33-38, 1998, walls are formed that define the channels rather than simply forming trenches in the substrate.
- a fluid within an open ended channel contains a partition, such as droplets, liposomes, emulsions, etc.
- the liquid partitions may have one compartment, or may have multiple compartments.
- the compartments may be aqueous based or oil based.
- a partition may contain both aqueous and oil based compartments.
- the compartment may contain cells, viruses, bacteria, molecules, compounds, elements, nucleic acids, etc., both in singular or plural form.
- a fluid compartment may encase another fluid compartment.
- a fluid compartment may encase multiple fluid compartments.
- the fluid compartments within a fluid compartment may contain the same or different cell types.
- a fluid compartment may contain a fluid compartment containing heart cells.
- Another fluid compartment may contain liver cells.
- Fluid compartments contained with a fluid compartment may contain the same or differing fluid types.
- a liposome is an artificially- prepared spherical vesicle composed of a lamellar phase lipid bilayer. Liposomes are often composed of phosphatidylcholine-enriched phospholipids and may also contain mixed lipid chains with surfactant properties such as egg phosphatidylethanolamme. A liposome design may employ surface ligands. A liposome encapsulates a region of aqueous solution inside a hydrophobic membrane. Hydrophobic chemicals can be dissolved into the membrane, and therefore, the liposome can carry both hydrophobic molecules and hydrophilic molecules.
- a fluid compartment may be a liposome, or a fluid compartment may contain liposomes.
- Liposomes are prepared by disrupting biological membranes (such as by sonication).
- liposomes are formed when thin lipid films or lipid cakes are hydrated and stacks of liquid crystalline bilayers become fluid and swell.
- the hydrated lipid sheets detach during agitation and self-close to form large, multilamellar vesicles (LMV) which prevents interaction of water with the hydrocarbon core of the bilayer at the edges.
- LMV multilamellar vesicles
- lipid formulations can vary depending on the composition (cationic, anionic, neutral lipid species), however, similar preparation method can be used for all lipid vesicles regardless of composition. See for example “Liposomes in Gene Delivery,” Danilo D. Lasic, 1997, CRC Press LLC. Generally, the procedure involves preparation of the lipid for hydration, hydration with agitation, and sizing to a homogeneous distribution of vesicles. When preparing liposomes with mixed lipid composition, the lipids are dissolved and mixed in an organic solvent to assure a homogeneous mixture of lipids. Once the lipids are thoroughly mixed in the organic solvent, the solvent is removed to yield a lipid film.
- the solvent may be evaporated using a dry nitrogen or argon stream in a fume hood.
- the organic solvent is removed by rotary evaporation yielding a thin lipid film on the sides of a round bottom flask.
- the lipid solution is transferred to containers and frozen by placing the containers on a block of dry ice or swirling the container in a dry ice- acetone or alcohol (ethanol or methanol) bath. Dry lipid films or cakes can be removed from the vacuum pump, the container close tightly and taped, and stored frozen until ready to hydrate. Hydration of the dry lipid film/cake is accomplished simply by adding an aqueous medium to the container of dry lipid and agitating.
- the lipid suspension should be maintained above the Tc during the hydration period.
- the hydration medium is generally determined by the application of the lipid vesicles. Suitable hydration media include distilled water, buffer solutions, saline, and nonelectrolytes such as sugar solutions.
- Physiological osmolality (290 mOsm/kg) is recommended for in vivo applications. Generally accepted solutions with meet these conditions are 0.9% saline, 5% dextrose, and 10% sucrose. During hydration some lipids form complexes unique to their structure. The product of hydration is a large, multilamellar vesicle (LMV). Once a stable, hydrated LMV suspension has been produced, the particles can be downsized by a variety of techniques, including sonication or extrusion. Disruption of LMV suspensions using sonic energy (sonication) typically produces small, unilamellar vesicles (SUV) with diameters in the range of 15-50 nm.
- sonic energy sonication
- Second-generation liposomes may be incorporated into the present invention.
- Second- generation liposomes, or long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle.
- the surface of the liposomes may be modified.
- PEG polymer poly-(ethylene glycol)
- the presence of PEG on the surface of the liposomal carrier has been shown to extend blood-circulation time while reducing mononuclear phagocyte system uptake (stealth liposomes). See Immordino et al, Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential, Int J Nanomedicine. Sep 2006; 1(3): 297-315.
- Methods of the invention may incorporate micelles, an aggregate of surfactant molecules dispersed in a liquid colloid.
- a typical micelle in aqueous solution forms an aggregate with the hydrophilic "head” regions in contact with surrounding solvent, sequestering the hydrophobic single-tail regions in the micelle center.
- This phase is caused by the packing behavior of single- tail lipids in a bilayer.
- the difficulty filling all the volume of the interior of a bilayer, while accommodating the area per head group forced on the molecule by the hydration of the lipid head group, leads to the formation of the micelle.
- This type of micelle is known as a normal- phase micelle (oil-in-water micelle).
- Inverse micelles have the head groups at the center with the tails extending out (water-in-oil micelle).
- Micelles are approximately spherical in shape. Other phases, including shapes such as ellipsoids, cylinders, and bilayers, are also possible.
- the shape and size of a micelle are a function of the molecular geometry of its surfactant molecules and solution conditions such as surfactant concentration, temperature, pH, and ionic strength.
- the process of forming micelles is known as micellisation and forms part of the phase behavior of many lipids according to their polymorphism.
- the droplets are composed of three layers: an internal aqueous phase layer, an inner oil phase layer, and an external aqueous phase layer.
- the droplet may contain an external oil phase layer.
- the external oil layer encompasses two aqueous compartments.
- the oil phase layer is a thin layer separating the internal and external aqueous phases.
- the thin oil phase layer has a high permeability, serving as a thin membrane between the two aqueous compartments.
- the oil phase layer can be less than 50 microns thick, less than 30 microns thick, less than 20 microns thick, less than 10 microns thick, less than 5 microns thick, or less than 1 micron thick.
- the external oil layer contains multiple aqueous compartments, where each aqueous compartment is surrounded by an oil layer.
- the droplets may be spherical or substantially spherical; however, in other cases, the droplets may be non-spherical.
- the droplets may have the appearance of blobs or other irregular shapes, for instance, depending on the external environment.
- a first fluid is surrounded by a second fluid if a closed loop can be drawn or idealized around the first fluid through only the second fluid.
- An oil or an aqueous fluid phase can include a biological/chemical material.
- the biological/chemical material can be tissues, cells, particles, proteins, antibodies, amino acids, nucleic acids, nucleotides, small molecules, and pharmaceuticals.
- the biological/chemical material can include one or more labels known in the art.
- the label can be a DNA tag, dyes or quantum dot, or combinations thereof.
- emulsion generally refers to a preparation of one liquid distributed in small globules (also referred to herein as drops or droplets) in the body of a second liquid.
- the first and second fluids are immiscible with each other.
- the partitions may be liposomes, micelles, emulsions, droplets, etc. or any combination thereof.
- a partition may include multiple compartments, or other partitions within a partition.
- a liposome can contain at least one other liposome.
- a liposome may contain an emulsion, or a droplet.
- a liposome may contain multiple emulsions or droplets.
- a droplet may contain at least one liposome.
- the partitions can be arranged in any configuration. Partitions with multiple compartments may be formed by using channels and flowing streams of fluids. As shown in FIG. 5 A, an aqueous fluid 100 is flowed in a channel.
- the fluid can be flowed at any speed or velocity, for example, at a rate of 0.1-1.0 microliters/min, at a rate of 1.0-2.0 microliters/min, or a rate greater than 2.0 microliters/min.
- the aqueous fluid 100 is flowed into an oil stream 110, or an immiscible fluid.
- the immiscible fluid 110 may be flowed at any rate, including at a rate of 0.1 - 1.0 microliters/min, at a rate of 1.0-2.0 microliters/min, or a rate greater than 2.0 microliters/min.
- the flowing of aqueous fluid 100 into an immiscible fluid creates aqueous partitions 120 in oil.
- An aqueous fluid containing a surfactant 130 is flowed into the stream of aqueous partitions 120 in oil.
- the rate of flow can be at a rate of 0.1 - 1.0 microliters/min, at a rate of 1.0-2.0 microliters/min, or a rate greater than 2.0 microliters/min.
- double emulsions 140 and oil droplets 150 are formed from the flowing of the aqueous fluid containing a surfactant 130 into the stream of aqueous fluids 120 in oil.
- the oil droplets 150 separate the double emulsions 140.
- the double emulsions 140 contain an oil membrane 141, an internal aqueous phase 142, and an external aqueous phase 143.
- methods of the invention may utilize partitions that have multiple compartments.
- a stem cell may be contained within the internal aqueous phase (142).
- the external aqueous phase 143 may contain a virus, a drug compound, or other agent that is able to transverse the oil membrane 141 and contact the stem cell.
- the partitions are aqueous partitions that are surrounded by an immiscible carrier fluid. In other embodiments, the partitions are non-aqueous partitions surrounded by an immiscible fluid, such as oil partitions in a water continuous phase.
- the sample fluid is aqueous, such as when employing a culture medium.
- the sample fluid is typically an aqueous buffer solution, such as ultrapure water (e.g., 18 mega-ohm resistivity, obtained, for example by column chromatography), 10 mM Tris HC1 and 1 mM EDTA (TE) buffer, phosphate buffer saline (PBS) or acetate buffer. Any liquid or buffer that is physiologically compatible with the sample can be used.
- the sample fluid comprises cell medium, as disclosed above.
- the sample fluid comprises the necessary components to ensure cell health and growth. As discussed above, any laboratory produced or commercially available cell medium may be employed.
- the carrier fluid is one that is immiscible with the sample fluid.
- the carrier fluid can be a non-polar solvent, decane (e g., tetradecane or hexadecane), fluorocarbon oil, silicone oil or another oil (for example, mineral oil).
- the carrier fluid has a high surface tension and therefore, is retained a microfluidic channel at an open end.
- the carrier fluid forms a meniscus at the open end of the microfluidic channel, caused by surface tension.
- the meniscus can be either convex or concave, depending on the carrier fluid and the surface of the microfluidic channel.
- the diameter of a partition, in a non-spherical partition is the mathematically-defined average diameter of the partition, integrated across the entire surface.
- the average diameter of a partition (and/or of a plurality or series of partitions) may be, for example, less than 3 mm, less than about 1 mm, less than about 500 micrometers, less than about 200 micrometers, less than about 100 micrometers, less than about 75 micrometers, less than about 50 micrometers, less than about 25 micrometers, less than about 10 micrometers, or less than about 5 micrometers in some cases.
- the average diameter may also be at least about 1 micrometer, at least about 2 micrometers, at least about 3 micrometers, at least about 5 micrometers, at least about 10 micrometers, at least about 15 micrometers, or at least about 20 micrometers in certain cases.
- Partitions may vary in size, where a first type partition is larger than a second type partition.
- the aqueous phase is typically an aqueous buffer solution, such as ultrapure water (e.g., 18 mega-ohm resistivity, obtained, for example by column
- the aqueous fluid may be cell medium, for either maintaining or growing cells.
- the aqueous phase or aqueous liquid may be immiscible with the oil phase liquid, such as a non- polar solvent, decane (e g., tetradecane or hexadecane), fluorocarbon oil, corn oil, silicone oil or another oil (for example, mineral oil).
- the carrier fluid contains one or more additives, such as agents which increase, reduce, or otherwise create non-Newtonian surface tensions (surfactants) and/or stabilize partitions against spontaneous coalescence on contact.
- Surfactants can include Tween, Span, fluorosurfactants, and other agents that are soluble in oil relative to water.
- performance is improved by adding a second surfactant, or other agent, such as a polymer or other additive, to the sample fluid.
- Surfactants can aid in controlling or optimizing partition size, flow and uniformity.
- the surfactant can serve to stabilize aqueous emulsions in fluorinated oils from coalescing.
- the partitions, or fluids within the partitions may be coated with or contain a surfactant or a mixture of surfactants.
- Preferred surfactants that may be added to the carrier fluid include, but are not limited to, surfactants such as sorbitan-based carboxylic acid esters (e.g., the "Span” surfactants, Fluka Chemika), including sorbitan monolaurate (Span 20), sorbitan monopalmitate (Span 40), sorbitan monostearate (Span 60) and sorbitan monooleate (Span 80), and perfluorinated polyethers (e.g., DuPont Krytox 157 FSL, FSM, and/or FSH).
- Other non-limiting examples of non-ionic surfactants which may be used include
- polyoxyethylenated alkylphenols for example, nonyl-, p-dodecyl-, and dinonylphenols
- polyoxyethylenated straight chain alcohols for example, polyoxyethylenated polyoxypropylene glycols, polyoxyethylenated mercaptans
- long chain carboxylic acid esters for example, glyceryl and polyglycerl esters of natural fatty acids, propylene glycol, sorbitol, polyoxyethylenated sorbitol esters, polyoxyethylene glycol esters, etc.
- alkanolamines e.g., diethanolamine-fatty acid condensates and isopropanolamine-fatty acid condensates.
- the partitions may contain more than one particle or can contain no more than one particle.
- each partition may contain, on average, no more than one cell.
- each partition may contain multiple cells.
- the partitions can be detected and/or sorted according to their contents.
- the concentration (i.e., number) of molecules, compounds, viruses, bacteria, cells or particles in a partition can influence sorting efficiently and therefore is preferably optimized.
- the concentration may be dilute enough that most of the partitions contain no more than a single molecule, cell or particle, with only a small statistical chance that a partition will contain two or more molecules, cells or particles. This may be to ensure that for the large majority of measurements, the level of reporter measured in each partition as it passes through the detection module corresponds to a single molecule, cell or particle and not to two or more molecules, cells or particles.
- the partitions may contain a plurality or non-diluted concentration of cells, viruses, bacteria, molecules, compounds, etc.
- the fluidic partition may contain additional entities, for example, other chemical, biochemical, or biological entities (e.g., dissolved or suspended in the fluid), cells, particles, gases, molecules, or the like.
- a partition may contain cells and molecules, or cells and viruses.
- a partition does not need to be homogeneous.
- the partition may each be substantially the same shape or size, as discussed above.
- the invention provides for the production of partition consisting essentially of a substantially uniform number of entities of a species therein (i.e., molecules, cells, particles, etc.).
- a substantial number of fluidic partition produced may each contain 1 entity, 2 entities, 3 entities, 4 entities, 5 entities, 7 entities, 10 entities, 15 entities, 20 entities, 25 entities, 30 entities, 40 entities, 50 entities, 60 entities, 70 entities, 80 entities, 90 entities, 100 entities, etc., where the entities are molecules or macromolecules, cells, particles, etc., or any combination thereof.
- the partition of fluid may be screened or sorted for those partition of fluid containing the species as further described below (e.g., using fluorescence or other techniques such as those described above), and in some cases, the partitions may be screened or sorted for those partition of fluid containing a particular number or range of entities of the species of interest, e.g., as previously described.
- a plurality or series of fluidic partitions may be enriched (or depleted) in the ratio of partition that do contain the species, for example, by a factor of at least about 2, at least about 3, at least about 5, at least about 10, at least about 15, at least about 20, at least about 50, at least about 100, at least about 125, at least about 150, at least about 200, at least about 250, at least about 500, at least about 750, at least about 1000, at least about 2000, or at least about 5000 or more in some cases.
- the enrichment may be in a ratio of at least about 104, at least about 105, at least about 106, at least about 107, at least about 108, at least about 109, at least about 1010, at least about 1011, at least about 1012, at least about 1013, at least about 1014, at least about 1015, or more.
- a fluidic partition containing a particular species may be selected from a library of fluidic partition containing various species, where the library may have about 100, about 103, about 104, about 105, about 106, about 107, about 108, about 109, about 1010, about 1011, about 1012, about 1013, about 1014, about 1015, or more items, for example, a DNA library, an RNA library, a protein library, a combinatorial chemistry library, etc.
- the partitions carrying the species may then be fused, reacted, or otherwise used or processed, etc., as further described below, for example, to initiate or determine a reaction.
- the partition may comprise sample fluid, discussed below.
- the sample fluid may comprise cell medium.
- the cell medium provides the necessary nutrients, growth factors, and hormones for cell growths, as well as regulating the pH and the osmotic pressure of the culture.
- the cell culture medium may allow for and support growth of the cells thus being cultured, or the cell medium is a maintenance medium. Growth is understood as an increase in viable cell density during at least a certain period of the cell culture.
- a maintenance medium is a cell culture medium which supports cell viability but which does not encourage cell growth. See for example, cell culture medium related patents: US Patent 4,038,139, 1977; US Patent 7,258,998, 2007; US Patent App.
- the growth medium controls the pH of the culture and buffers the cells in culture against fluctuations in the pH. This buffering may be achieved by including an organic (e.g., HEPES) or C02 bicarbonate based buffer. Control of pH is needed to ensure the growth and health of cells in culture. Most normal mammalian cell lines grow well at pH 7.4, and there is very little variability among different cell strains.
- stem cells may be used.
- Induced pluripotent stem cells also known as iPS cells or iPSCs
- iPSCs are a type of pluripotent stem cell that can be generated directly from adult cells.
- iPSCs are typically derived by introducing a specific set of pluripotency-associated genes, or "reprogramming factors," into a given cell type.
- the original set of reprogramming factors also dubbed Yamanaka factors
- Somatic cells may be reprogrammed into induced pluripotent stem cells (iPSCs) using known methods such as the use of defined transcription factors.
- iPSCs induced pluripotent stem cells
- the iPSCs are characterized by their ability to proliferate indefinitely in culture while preserving their developmental potential to differentiate into derivatives of all three embryonic germ layers.
- fibroblasts are converted to iPSC by methods such as those discussed in Takahashi and
- Induction of pluripotent stem cells from adult fibroblasts can be done by methods that include introducing four factors, Oct3/4, Sox2, c-Myc, and Klf4, under ES cell culture conditions.
- Human dermal fibroblasts (HDF) are obtained.
- a retroviruse containing human Oct3/4, Sox2, Klf4, and c-Myc is introduced into the HDF.
- the cells are harvested by trypsinization and plated onto mitomycin C-treated SNL feeder cells. See, e.g., McMahon and Bradley, 1990, Cell 62: 1073-1085.
- DMEM containing 10% FBS fetal calf serum
- bFGF basic fibroblast growth factor
- iPS cells can be transfected to model a particular disease.
- iPS cells can also be used in modeling of infectious diseases.
- Human induced pluripotent stem cells iPSCs
- iPSCs offer the ability to produce host-specific differentiated cells and thus have the potential to transform the study of infectious disease; and iPSC models of infectious disease have been described.
- Hepatocyte-like cells derived from iPSCs support the entire life cycle of hepatitis C virus, including inflammatory responses to infection, enabling studies of how host genetics impact viral pathogenesis. See Schwartz et al, 2012, PNAS
- the partitions may contain any biological or non-biological agent.
- the partitions contain cells.
- the partitions contain at least one molecule, at least one compound, or at least one element.
- the partitions contain iPS cells.
- the partitions contain iPS cells differentiated into varying cell types.
- a partition may contain one cell type while another partition contains a different cell type.
- a partition may contain heart cells while another partition contains lung cells.
- the cells may be proximate to allow for cell-cell communication or signaling, or the cells may be separated to reduce signaling or other forms of cell-cell communication.
- methods of the invention are used for chemical synthesis reactions or biological or chemical assays, such as sample preparation and analysis in a variety of fields in the art, including without limitation for many fields such as DNA sequencing, microarray sample preparation, genotyping, gene expression, biodefense, food monitoring, forensics, disease modeling, drug investigations, proteomics and cell biology.
- any material or species may be enveloped in a partition and processed in the device of the invention.
- samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases.
- Biological samples include, without limitation, cells and any components thereof, blood products, such as plasma, serum and the like, proteins, peptides, amino acids, polynucleotide, lipids, carbohydrates, and any combinations thereof.
- the sample may include chemicals, organic or inorganic, used to interact with the interactive material.
- Environmental samples include environmental material such as surface matter, soil, water, crystals and industrial samples.
- a microfluidic system 8 comprises a first substrate 20 with at least one reservoir 12 in fluid communication with an upper opening 11 at an upper surface 10 of the first substrate 20 and a lower opening 24 at a lower surface 25 of the first substrate 20, wherein the lower opening 24 is dimensioned such that a liquid 16 held in the reservoir 12 is prevented from flowing through the lower opening 24 and into ambient atmosphere by surface tension.
- the microfluidic system 8 also comprises a mechanical subsystem 9 supporting the first substrate 20 in an orientation such that liquid dispensed to the upper opening 11 flows into the reservoir 12.
- the mechanical subsystem 9 comprises an upper rail 14 and a lower rail 15.
- the microfluidic system 8 also comprises a second substrate 21 coupled to 22 and controlled by the mechanical subsystem 9, the second substrate 21 comprising a receptacle 19 open to a surface 26 of the second substrate 21, wherein operation of the mechanical subsystem 9 while a liquid 16 is held within the reservoir 12 brings the second substrate 21 into contact with a surface of the liquid 16, causing the liquid 16 to flow into the receptacle 19.
- the systems are coupled or operably linked to a mechanical subsystem 9 comprising a chassis 13.
- a substrate of the invention may be operably coupled to a drive rail 17 which is operably connected to a motor 18, such that operation of the motor causes movement of the drive rail 17 which slides a substrate 21 which is coupled to a rail 15 by an attachment configuration 22.
- Methods of the present invention may incorporate cell culturing.
- Cell culturing devices are commercially available, however, each of the currently available systems have at least, the following limitations: large size; high cost (particularly robotics); possible contamination, use of large scale cultures; treating cells with an enzyme; requiring complex software and using a large cell volume.
- Commercially available cell automation systems are developed by combining robotic stages, however, these systems are expensive given the cost of the robotic arms and the software used to drive them.
- the specific culture conditions may vary depending on the cell type. However, most culture conditions consist of a suitable vessel containing a substrate or medium that supplies the essential nutrients (amino acids, carbohydrates, vitamins, and minerals), growth factors, hormones and gases (02, C02). Furthermore, the physicochemical environment (pH, osmotic pressure, temperature) must be regulated. Cells may be grown floating in the culture medium (suspension culture) or grown while attached to a solid or semi-solid substrate (adherent or monolayer culture). In some embodiments, the devices and systems may be kept in an isothermal environment.
- Cells are grown and maintained at an appropriate temperature and gas mixture (typically, 37 °C, 5% C02 for mammalian cells), usually in a cell incubator. Culture conditions vary widely for each cell type, and variation of conditions for a particular cell type can result in different phenotypes. See for example, Tsai et al., "Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol," Hum. Reprod. (2004) 19 (6): 1450-1456.
- A-MEM amniotic fluid-derived mesenchymal stem cells
- a-MEM a-MEM supplemented with 10% FBS, 0.1 ⁇ / ⁇ dexamethason, 10 mmol/1 ⁇ -glycerol phosphate, 50 ⁇ / ⁇ ascorbate
- adipogenic medium a-MEM supplemented with 10%> FBS, 1 ⁇ / ⁇ dexamethasone, 5 ⁇ g/ml insulin, 0.5 mmol/1 isobutylmethylxanthine and 60 ⁇ / ⁇ indomethacin
- AFMSCs were incubated with a- MEM supplemented with 20% FBS, 1 mmol/1 ⁇ -mercaptoethanol, 5 ng/ml bFGF (Sigma, St Louis) for 24 h, and then treated with serum depletion for 5 h.
- the cell medium provides the necessary nutrients, growth factors, and hormones for cell growths, as well as regulating the pH and the osmotic pressure of the culture.
- the cell culture medium according to the present invention is a medium allowing for and supporting growth of the animal cells thus cultured. Growth is understood as an increase in viable cell density during at least a certain period of the cell culture. According to the present invention, such definition of 'growth medium' is to be understood as being opposed to the term 'maintenance medium' in its usual meaning in the art.
- a maintenance medium is a cell culture medium which supports cell viability but which does not encourage cell growth. Often, such maintenance media do not contain essential growth factors such as transferrin, insulin, albumin and the like. See for example, cell culture medium related patents: US Patent 4,038,139; US Patent 7,258,998; and US Patent 8,338,177, each incorporated by reference.
- the growth medium controls the pH of the culture and buffers the cells in culture against fluctuations in the pH.
- This buffering may be achieved by including an organic (e.g., HEPES) or C02 bicarbonate based buffer.
- Control of pH is needed to ensure the growth and health of cells in culture.
- Most normal mammalian cell lines grow well at pH 7.4, and there is very little variability among different cell strains.
- some transformed cell lines have been shown to grow better at slightly more acidic environments (pH 7.0-7.4), and some normal fibroblast cell lines prefer slightly more basic environments (pH 7.4-7.7). Because the pH of the medium is dependent on the delicate balance of dissolved carbon dioxide (C02) and bicarbonate (HC03), changes in the atmospheric C02 can alter the pH of the medium.
- C02 dissolved carbon dioxide
- HC03 bicarbonate
- the optimal temperature for cell culture largely depends on the body temperature of the host from which the cells were isolated, and to a lesser degree on the anatomical variation in temperature (e.g., temperature of the skin may be lower than the temperature of skeletal muscle). Overheating is a more serious problem than under heating for cell cultures; therefore, often the temperature in the incubator is set slightly lower than the optimal temperature.
- Most human and mammalian cell lines are maintained at 36°C to 37°C for optimal growth. Insect cells are cultured at 27°C for optimal growth; they grow more slowly at lower temperatures and at temperatures between 27°C and 30°C. Above 30°C, the viability of insect cells decreases, and the cells do not recover even after they are returned to 27°C. Avian cell lines require 38.5°C for maximum growth.
- Subculturing is the removal of the medium and transfer of cells from a previous culture into fresh growth medium, a procedure that enables the further propagation of the cell line or cell strain.
- the culture has to divided and fresh medium supplied. For example, subculturing could be needed if a drop in pH is observed.
- a drop in the pH of the growth medium usually indicates a buildup of lactic acid, which is a by-product of cellular metabolism. Lactic acid can be toxic to the cells, and the decreased pH can be sub- optimal for cell growth.
- cell viability is determined by staining the cells with trypan blue. As trypan blue dye is permeable to non-viable cells or death cells whereas it is impermeable to this dye. Stain the cells with trypan dye and load to haemocytometer and calculate % of viable cells. Cell viability is calculated as the number of viable cells divided by the total number of cells within the grids on the hemacytometer. If cells take up trypan blue, they are considered non-viable. It would be appreciated by one skilled in the art for the optical detection of cells containing trypan blue.
- cells are encapsulated in partitions containing cell medium.
- the cells can be flowed from various chambers via the multichannel system of the invention.
- Microfluidic channels can be aligned to cause flow of the partitions into a humidifier chamber.
- mammalian cells are grown in humidified atmosphere at 37° C and 5% C02, in cell culture incubators.
- Microfluidic channels can be aligned to deliver C02 to the humidifier chamber within the multichannel system by aligning microfluidic channels that seal, or by an inlet microfluidic channel configured to deliver liquids or gases to the chamber. It should be appreciated that alignment of microfluidic channels of the invention can be sealed to allow for the transport of gases.
- the partitions are flowed from a chamber into the microfluidic channels to be merged or coalesced with fresh growth medium.
- partitions containing cells during culturing may be retained within microfluidic channels or chambers of the present invention. After merging or coalesced with fresh growth medium, the partitions may be retained within microfluidic channels, or the cells may be diverted to a chamber.
- cells are grown in nanoliter-microliter partitions in cell medium that is replenished every 2-3 days.
- cells may require splitting every 2-3 days.
- Media change involves adding one or more partitions of fresh media to a partition of incubated cells and thereby partially replenishing growth media. Merging of partitions is discussed above.
- Cells are further incubated in the combined partition or in smaller partitions generated by splitting the combined partition.
- Cell subculture or splitting is achieved similarly to media change by combining (merging and mixing) a partition of incubated cells and a partition of fresh media, splitting the combined partition, and repeating this procedure using the split partition(s) until a desired cell concentration is reached.
- Final partitions are then incubated, while other partitions of suspended cells generated in the subculturing process are discarded.
- Incubation can be accomplished within the microfluidic channels of the device, or in chambers of the device.
- One or more thermal regulators can be employed to ensure proper temperature.
- multiple partitions containing one kind or multiple kinds of cells are exposed to partitions containing one or multiple reagents and are assayed similarly to the assays described above.
- a multiplex device can also be used for multiplex cell culture, where cells can be grown and maintained in multiple partitions.
- iPS cells are encased in partitions containing cell medium and related growth factors.
- the iPS cell partitions are cultured by techniques and methods discussed above, or known in the art. iPS cell partitions can be merged with other materials and reactants, including maintenance medium, transfection reagents, etc. during the incubation process.
- iPS cell partitions may be used in expression profiling where target compounds are introduced into the partitions by methods disclosed herein.
- a threshold of expression is established.
- the threshold may be established by reference to literature or by using a reference sample from a subject known not to be afflicted with the disorder.
- the expression may be over-expression compared to the reference (i.e., an amount greater than the reference) or under-expression compared to the reference (i.e., an amount less than the reference).
- the iPS cell partitions are merged with partitions containing target compounds and allowed to further incubate, which may involve splitting of partitions, i.e. splitting of cell cluster, and merging of partitions, i.e. introduction of freshcell medium.
- Methods of the invention may be used to detect any disorder or compound effect.
- the iPS cell partitions may be flowed passed a detector to screen for abnormalities, or diverted to a collection chamber for analysis.
- genetically modified cells are used in the methods of the invention.
- genetic editing of stem cells or transfected stem cells is employed.
- Genetic or genome editing techniques may proceed by any suitable method such as zinc-finger domain methods, transcription activator-like effector nucleases (TALENs), or clustered regularly interspaced short palindromic repeat (CRISPR) nucleases.
- Genome editing may be used for, e.g., knocking out a gene, introducing a premature stop codon, interfering with a promoter region, or changing the function of an ion channel or other cellular protein.
- genome editing techniques are applied to the iPS cells. Using genome editing for modifying a chromosomal sequence, a control cell or cell line can be generated, or any other genetic variant of the first cell may be created.
- cells are maintained within droplets and monitored over a twenty-four hour period.
- the shuttle aligns for a period of time so only one droplet flows from the channel into the shuttle.
- the shuttle slides to align with another channel containing a solution.
- the shuttle aligns for a period of time to allow fluid from the channel to flow into the shuttle.
- the fluid containing the breast cancer cell and the solution containing the drug solution merge to form a droplet.
- the shuttle speed and alignment time controls the volume of the fluid flowing from the channel into the shuttle.
- the shuttle can align to allow any combination of the individual solutions to flow into the shuttle, thereby exposing the cells to any combination of the drug molecules.
- the droplets containing the breast cancer cells and the drug molecules are incubated within the system of the invention.
- a plurality of droplets of approximately 30 ⁇ ⁇ ⁇ volume containing at least one breast cancer cell and a fluid volume are formed.
- the fluid may comprise a control solution (lacking a drug molecule), may comprise at least one type of drug molecule, or may comprise multiple drug molecules.
- Droplets containing the MCF7 breast cancer cell and the drug molecule Doxorubicin are formed.
- Droplets containing the MCF7 breast cancer cell and the drug molecule Cisplatin are formed.
- Droplets containing the MCF7 breast cancer cell and the drug molecule Cytoxan are formed.
- Droplets containing the MCF7 breast cancer cell and the drug molecules Doxorubicin, Cisplatin, and Cytoxan are formed.
- FIG. 7 reports the viability of the cells within the droplets over a 24 hour period. As shown in FIG. 7, the droplets containing the MCF7 breast cancer cells shows a nearly 100% viability after 24 hours. Droplets containing the MCF7 breast cancer cells and the drug Doxoruicin yield 58% viability after 24 hours. Droplets containing the MCF7 breast cancer cells and the drug Cisplatin showed 45% cell viability after 24 hours. Droplets containing the MCF7 breast cancer cells and the drug Cytoxan showed 73% cell viability after 24 hours.
- cells can be maintained within the system, exposed to various drug combinations, and analyzed to determine the effects of the drug or drug combination on the cells. It should be appreciated that other cell characteristics can be measured to determine the effects of the drug molecules on the cells. For example, protein levels can be analyzed, enzyme levels can be analyzed, or the cells can be assayed for the presence or absence of a cell product or cellular component.
- the methods and systems of the invention can be used to determine dose response curves.
- droplets containing at least one bacterial cell of E. coli were monitored over a three hour period.
- the droplet containing the E.coli cells were exposed to various concentrations of the antibiotic Amoxicillin. After three hours, the droplets were analyzed for cell viability. As shown in FIG. 8, cell viability was reduced over increasing values in
- concentration of drugs that causes cell death can be determined.
- concentration of drugs that causes cell death can be determined.
- dose response curves were developed for the determination of the combination of Penicillin and Streptomycin on E. Coli cells.
- the antibiotics Penicillin and Streptomycin were contained within 30 droplets containing E. Coli cells.
- the cells were analyzed after three hours for cell viability. The results are reported in FIG. 9.
- concentrations of a drug that result in cell death can be determined.
- the cells may be assayed by any known technique in the art.
- the cells may be analyzed for the expression of a protein, or for the absence of a protein.
- the cells may be analyzed for any change in cellular function or for any cellular product.
- MCF-7 breast cancer cells are contained within 30 droplets. It should be appreciated that droplets of any volume can be created by the system of the invention. A plurality of droplets containing MCF-7 cells was created using the systems of the invention. MCF-7 cell containing droplets were exposed to the drug Imatinib. A plurality of droplets was exposed to the drug at various concentrations. MCF-7 cell containing droplets were exposed to the drug arsenic trioxide. A plurality of droplets was exposed to the drug at various concentrations. MCF-7 cell containing droplets were exposed to the drug etoposide. A plurality of droplets was exposed to the drug at various concentrations. The cells were cultured in the system of the invention and then analyzed after a 24 hour period. The plurality of droplets was analyzed for cell viability. FIG. 10 shows the dose response curve for each of the drugs at the various concentrations. As shown in FIG. 10, the optimum concentration for the drug to kill the cancer cells can be determined.
- iPSC were contained within droplets using the systems and methods of the invention.
- the cells were cultured in 1 ⁇ droplets and monitored over a 24 hour period. Some of the droplets were exposed to Imatinib, Cisplatin, and the combination of Imatinib and Cisplatin. As shown in FIG. 11, the combination of Imatinib and Cisplatin showed an increase in cell viability compared to Cisplatin alone.
- FIGS. 12, 13A and 13B show the results of culturing and growing cells in droplets formed and maintained in the systems of the invention.
- iPSCs were cultured in 20 ⁇ , hanging droplets in open-ended well plates, encapsulated in oil. See copending application 62/115,877 filed February 13, 2015, the contents of which is incorporated by reference in its entirety.
- the iPS cells shown in panel B of FIG. 12 were cultured in 1 ⁇ ⁇ hanging droplets in open-ended well plates.
- the cell number increased, or the collection of cells grew over a 24 hour period in both 20 ⁇ _, hanging droplets and 1 hanging droplets.
- FIG. 13 shows that the number of cells increase over a 24 hour period.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Clinical Laboratory Science (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Sustainable Development (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Fluid Mechanics (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461993119P | 2014-05-14 | 2014-05-14 | |
US201562115877P | 2015-02-13 | 2015-02-13 | |
US201562115872P | 2015-02-13 | 2015-02-13 | |
PCT/IB2015/001469 WO2015173652A1 (en) | 2014-05-14 | 2015-05-14 | Method for testing compounds on living cells |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3142791A1 true EP3142791A1 (de) | 2017-03-22 |
Family
ID=54199269
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15770965.0A Not-in-force EP3142790B8 (de) | 2014-05-14 | 2015-05-14 | Methode zur handhabung von flüssigkeiten in einer mikrofluidischen vorrichtung mit kanalplatten |
EP15771240.7A Withdrawn EP3142791A1 (de) | 2014-05-14 | 2015-05-14 | Verfahren zum testen von verbindungen auf lebenden zellen |
EP19157685.9A Withdrawn EP3539662A1 (de) | 2014-05-14 | 2015-05-14 | Mikrofluidischer apparat zur handhabung von flüssigkeiten |
EP15774678.5A Withdrawn EP3142792A2 (de) | 2014-05-14 | 2015-05-14 | Mikrofluidische vorrichtungen mit relativ zueinander verschiebbaren kanälen und verfahren zur verwendung davon |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15770965.0A Not-in-force EP3142790B8 (de) | 2014-05-14 | 2015-05-14 | Methode zur handhabung von flüssigkeiten in einer mikrofluidischen vorrichtung mit kanalplatten |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19157685.9A Withdrawn EP3539662A1 (de) | 2014-05-14 | 2015-05-14 | Mikrofluidischer apparat zur handhabung von flüssigkeiten |
EP15774678.5A Withdrawn EP3142792A2 (de) | 2014-05-14 | 2015-05-14 | Mikrofluidische vorrichtungen mit relativ zueinander verschiebbaren kanälen und verfahren zur verwendung davon |
Country Status (4)
Country | Link |
---|---|
US (3) | US20170216838A1 (de) |
EP (4) | EP3142790B8 (de) |
CA (3) | CA2948979A1 (de) |
WO (3) | WO2015173652A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016207721A1 (en) * | 2015-06-25 | 2016-12-29 | University Of Limerick | Mechanical device for generating combinatorial library |
WO2017035484A1 (en) * | 2015-08-26 | 2017-03-02 | EMULATE, Inc. | Perfusion manifold assembly |
WO2018049250A1 (en) * | 2016-09-08 | 2018-03-15 | Curematch, Inc. | Optimizing therapeutic options in personalized medicine |
WO2018115978A2 (en) | 2016-12-23 | 2018-06-28 | University Of Limerick | Water-in-oil-in water emulsions for analysis of biological and chemical samples |
WO2018183744A1 (en) | 2017-03-29 | 2018-10-04 | The Research Foundation For The State University Of New York | Microfluidic device and methods |
WO2022008641A1 (en) * | 2020-07-08 | 2022-01-13 | Roche Sequencing Solutions, Inc. | Split-pool synthesis apparatus and methods of performing split-pool synthesis |
KR102423154B1 (ko) * | 2021-04-13 | 2022-07-20 | 주식회사 시큐어메드 | 전도성 플라스틱을 이용한 진단 장치 및 그 장치의 제조 방법 |
WO2024014767A1 (ko) * | 2022-07-15 | 2024-01-18 | 주식회사 시큐어메드 | 전도성 폴리머를 이용한 액적 액추에이터 및 그것의 전극 구조 |
KR20240037491A (ko) * | 2022-09-15 | 2024-03-22 | 삼성전자주식회사 | 유전자 증폭 칩, 유전자 증폭 장치 및 생체입자 분석 장치 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1051259A1 (de) * | 1998-01-12 | 2000-11-15 | Massachusetts Institute Of Technology | Verfahren und vorrichtung zur mikrotestdurchführung |
US20020001546A1 (en) * | 1998-01-12 | 2002-01-03 | Massachusetts Institute Of Technology | Methods for screening substances in a microwell array |
US20020151040A1 (en) * | 2000-02-18 | 2002-10-17 | Matthew O' Keefe | Apparatus and methods for parallel processing of microvolume liquid reactions |
US20030124599A1 (en) * | 2001-11-14 | 2003-07-03 | Shiping Chen | Biochemical analysis system with combinatorial chemistry applications |
US20100261159A1 (en) * | 2000-10-10 | 2010-10-14 | Robert Hess | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
US20110217711A1 (en) * | 2010-03-02 | 2011-09-08 | Quantalife, Inc. | Assays with droplets transformed into capsules |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2771398A (en) * | 1953-09-17 | 1956-11-20 | Thomas L Snyder | Method and apparatus for counting microorganisms |
GB1138401A (en) | 1965-05-06 | 1969-01-01 | Mallory & Co Inc P R | Bonding |
US3506424A (en) | 1967-05-03 | 1970-04-14 | Mallory & Co Inc P R | Bonding an insulator to an insulator |
US3997396A (en) * | 1973-07-02 | 1976-12-14 | Monsanto Company | Method for the in vitro propagation and maintenance of cells |
US4038139A (en) | 1976-07-16 | 1977-07-26 | G. D. Searle & Co., Limited | Cell culture medium |
US5310674A (en) * | 1982-05-10 | 1994-05-10 | Bar-Ilan University | Apertured cell carrier |
US4682890A (en) * | 1985-05-31 | 1987-07-28 | Health Research, Incorporated | Microsample holder and carrier therefor |
US5501959A (en) * | 1989-01-17 | 1996-03-26 | Alamar Biosciences Laboratory, Inc. | Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents |
US5262128A (en) * | 1989-10-23 | 1993-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Array-type multiple cell injector |
US5523162A (en) | 1990-04-03 | 1996-06-04 | Ppg Industries, Inc. | Water repellent surface treatment for plastic and coated plastic substrates |
US5284753A (en) * | 1991-03-20 | 1994-02-08 | Neuro Probe, Inc. | Multiple-site chemotactic test apparatus and method |
ES2325393T3 (es) * | 1993-10-28 | 2009-09-03 | Houston Advanced Research Center | Aparato poroso de flujo a traves microfabricado para la deteccion diferenciada de reacciones de union. |
US6001586A (en) * | 1996-03-29 | 1999-12-14 | Genencor International, Inc. | Compartmentalization method for screening microorganisms |
US5885470A (en) | 1997-04-14 | 1999-03-23 | Caliper Technologies Corporation | Controlled fluid transport in microfabricated polymeric substrates |
US5783431A (en) * | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
US6103479A (en) * | 1996-05-30 | 2000-08-15 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US6143496A (en) | 1997-04-17 | 2000-11-07 | Cytonix Corporation | Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly |
US20040241759A1 (en) * | 1997-06-16 | 2004-12-02 | Eileen Tozer | High throughput screening of libraries |
EP1060022A1 (de) * | 1998-02-04 | 2000-12-20 | Merck & Co., Inc. | Virtuelle bohrungen zur verwendung bei testen von assays hohen durchsatzes |
CA2367912A1 (en) * | 1999-03-19 | 2000-09-28 | Genencor International, Inc. | Multi-through hole testing plate for high throughput screening |
US6440706B1 (en) | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
US6524456B1 (en) * | 1999-08-12 | 2003-02-25 | Ut-Battelle, Llc | Microfluidic devices for the controlled manipulation of small volumes |
US6210986B1 (en) | 1999-09-23 | 2001-04-03 | Sandia Corporation | Microfluidic channel fabrication method |
CA2425476C (en) * | 2000-10-10 | 2011-02-01 | Biotrove, Inc. | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
AU2002243764A1 (en) | 2001-01-31 | 2002-08-19 | Sau Lan Tang Staats | Microfluidic devices |
EP1317960A1 (de) * | 2001-12-06 | 2003-06-11 | PamGene B.V. | System und Methode zur Analyse von Blutproben und zugehörige Wegwerfkartusche |
GB0208041D0 (en) | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
US20030199085A1 (en) * | 2002-04-22 | 2003-10-23 | Abraham Berger | Transportation of stem cells |
JP2006507921A (ja) | 2002-06-28 | 2006-03-09 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 流体分散のための方法および装置 |
US7244961B2 (en) * | 2002-08-02 | 2007-07-17 | Silicon Valley Scientific | Integrated system with modular microfluidic components |
US7041481B2 (en) | 2003-03-14 | 2006-05-09 | The Regents Of The University Of California | Chemical amplification based on fluid partitioning |
US7767435B2 (en) * | 2003-08-25 | 2010-08-03 | University Of Washington | Method and device for biochemical detection and analysis of subcellular compartments from a single cell |
ATE462493T1 (de) * | 2004-02-02 | 2010-04-15 | Silicon Valley Scient Inc | Integriertes system mit modularen mikrofluidischen komponenten |
WO2005080598A1 (ja) | 2004-02-19 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 体細胞核初期化物質のスクリーニング方法 |
CN101310169B (zh) * | 2005-11-16 | 2011-06-08 | 株式会社日立制作所 | 液滴生成运送方法和装置以及粒子操作装置 |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
US20100137163A1 (en) | 2006-01-11 | 2010-06-03 | Link Darren R | Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors |
WO2007133710A2 (en) | 2006-05-11 | 2007-11-22 | Raindance Technologies, Inc. | Microfluidic devices and methods of use thereof |
US8550503B2 (en) * | 2006-09-28 | 2013-10-08 | Stokes Bio Ltd. | Microfluidic connector |
EP2128244A4 (de) | 2007-01-18 | 2012-05-09 | Riken | Verfahren zur induktion/differenzierung zu einer photorezeptorzelle |
CN101802172A (zh) | 2007-05-30 | 2010-08-11 | 通用医疗公司 | 由体细胞产生多能细胞的方法 |
US20090047191A1 (en) * | 2007-06-08 | 2009-02-19 | Gafur Zainiev | Closed space disposable micro-reactor and uses thereof |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
US20100227767A1 (en) * | 2007-07-26 | 2010-09-09 | Boedicker James Q | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
US8357530B2 (en) * | 2007-08-01 | 2013-01-22 | National University Corporation Tokyo University Of Agriculture And Technology | Microfluidic device for trapping single cell |
US20100297747A1 (en) * | 2007-10-25 | 2010-11-25 | Manalis Scott R | System and method for monitoring cell growth |
WO2009121556A1 (en) * | 2008-03-31 | 2009-10-08 | Ese Gmbh | Sample holder and method of using the same |
US20100021437A1 (en) | 2008-04-07 | 2010-01-28 | The McLean Hospital Corporation Whitehead Institute for Biomedical Research | Neural stem cells derived from induced pluripotent stem cells |
US8622987B2 (en) * | 2008-06-04 | 2014-01-07 | The University Of Chicago | Chemistrode, a plug-based microfluidic device and method for stimulation and sampling with high temporal, spatial, and chemical resolution |
US8389294B2 (en) * | 2008-06-09 | 2013-03-05 | Wisconsin Alumni Research Foundation | Microfluidic device and method for coupling discrete microchannels and for co-culture |
US20100062534A1 (en) | 2008-09-09 | 2010-03-11 | The General Hospital Corporation | Inducible lentiviral vectors for reprogramming somatic cells |
US8697011B2 (en) | 2009-05-19 | 2014-04-15 | Stokes Bio Limited | Sampling device with immiscible fluid supply tube in counter-flow arrangement |
US9625454B2 (en) * | 2009-09-04 | 2017-04-18 | The Research Foundation For The State University Of New York | Rapid and continuous analyte processing in droplet microfluidic devices |
CA2781443A1 (en) * | 2009-11-20 | 2011-05-26 | Opx Biotechnologies, Inc. | Methods, systems, and compositions for microbial bio-production of biomolecules using syngas components, or sugars, as feedstocks |
US8535889B2 (en) | 2010-02-12 | 2013-09-17 | Raindance Technologies, Inc. | Digital analyte analysis |
US9327303B2 (en) | 2011-01-17 | 2016-05-03 | Agency For Science, Technology And Research | Microfluidic droplet generator |
PL395776A1 (pl) * | 2011-07-27 | 2013-02-04 | Instytut Chemii Fizycznej Polskiej Akademii Nauk | Sposób dzielenia kropel na zadanie w zlaczu mikroprzeplywowym |
KR20140140080A (ko) * | 2012-03-16 | 2014-12-08 | 라이프 테크놀로지스 코포레이션 | 생물학적 샘플을 포함하기 위한 시스템 및 방법 |
-
2015
- 2015-05-14 EP EP15770965.0A patent/EP3142790B8/de not_active Not-in-force
- 2015-05-14 EP EP15771240.7A patent/EP3142791A1/de not_active Withdrawn
- 2015-05-14 WO PCT/IB2015/001469 patent/WO2015173652A1/en active Application Filing
- 2015-05-14 US US15/310,607 patent/US20170216838A1/en not_active Abandoned
- 2015-05-14 CA CA2948979A patent/CA2948979A1/en not_active Abandoned
- 2015-05-14 CA CA2948975A patent/CA2948975A1/en not_active Abandoned
- 2015-05-14 EP EP19157685.9A patent/EP3539662A1/de not_active Withdrawn
- 2015-05-14 WO PCT/IB2015/001509 patent/WO2015173658A2/en active Application Filing
- 2015-05-14 EP EP15774678.5A patent/EP3142792A2/de not_active Withdrawn
- 2015-05-14 US US15/310,613 patent/US20170080426A1/en not_active Abandoned
- 2015-05-14 WO PCT/IB2015/001468 patent/WO2015173651A1/en active Application Filing
- 2015-05-14 CA CA2948976A patent/CA2948976A1/en not_active Abandoned
- 2015-05-14 US US15/310,600 patent/US20170080417A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1051259A1 (de) * | 1998-01-12 | 2000-11-15 | Massachusetts Institute Of Technology | Verfahren und vorrichtung zur mikrotestdurchführung |
US20020001546A1 (en) * | 1998-01-12 | 2002-01-03 | Massachusetts Institute Of Technology | Methods for screening substances in a microwell array |
US20020151040A1 (en) * | 2000-02-18 | 2002-10-17 | Matthew O' Keefe | Apparatus and methods for parallel processing of microvolume liquid reactions |
US20100261159A1 (en) * | 2000-10-10 | 2010-10-14 | Robert Hess | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
US20030124599A1 (en) * | 2001-11-14 | 2003-07-03 | Shiping Chen | Biochemical analysis system with combinatorial chemistry applications |
US20110217711A1 (en) * | 2010-03-02 | 2011-09-08 | Quantalife, Inc. | Assays with droplets transformed into capsules |
Non-Patent Citations (1)
Title |
---|
See also references of WO2015173652A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015173652A1 (en) | 2015-11-19 |
WO2015173658A2 (en) | 2015-11-19 |
CA2948979A1 (en) | 2015-11-19 |
EP3142790B1 (de) | 2019-03-20 |
US20170080426A1 (en) | 2017-03-23 |
WO2015173658A3 (en) | 2016-01-07 |
EP3142792A2 (de) | 2017-03-22 |
WO2015173651A1 (en) | 2015-11-19 |
US20170216838A1 (en) | 2017-08-03 |
EP3142790A1 (de) | 2017-03-22 |
US20170080417A1 (en) | 2017-03-23 |
EP3539662A1 (de) | 2019-09-18 |
CA2948975A1 (en) | 2015-11-19 |
EP3142790B8 (de) | 2019-04-24 |
CA2948976A1 (en) | 2015-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170080426A1 (en) | Device and method for testing compounds on living cells | |
Teixeira et al. | Emerging biotechnology applications of aqueous two‐phase systems | |
Göpfrich et al. | One-pot assembly of complex giant unilamellar vesicle-based synthetic cells | |
Mashaghi et al. | Droplet microfluidics: A tool for biology, chemistry and nanotechnology | |
US11229910B2 (en) | Microfluidic devices and systems for cell culture and/or assay | |
JP6791960B2 (ja) | 3d組織培養モデルの印刷方法 | |
EP2529238A2 (de) | Hängende tropfvorrichtungen, -systeme und/oder -verfahren | |
EP2895589B1 (de) | Vorrichtung zur stoffexposition | |
CA3137040A1 (en) | Microfluidic device and method of use for cell culture | |
CN102140422A (zh) | 用于控制不同种细胞相互作用的装置、其制备方法及用途 | |
EP3314046B1 (de) | Mechanische vorrichtung zur erzeugung einer kombinatorischen bibliothek | |
Li et al. | A controllable, centrifugal-based hydrodynamic microfluidic chip for cell-pairing and studying long-term communications between single cells | |
Guo et al. | A generic pump‐free organ‐on‐a‐chip platform for assessment of intestinal drug absorption | |
Chen et al. | On-Chip Octanol-Assisted Liposome Assembly for Bioengineering | |
US20220282192A1 (en) | Method and system for cultivating cells in media-exchanging wells | |
Lee et al. | Biomimetic engineering of a generic cell-on-membrane architecture by microfluidic engraving for on-chip bioassays |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20161202 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20180813 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: HOOKE BIO LIMITED |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200721 |